Search Results - "FLINK, Hajo J"

A Fatal Outcome after Cessation of Nucleotide Analogue Therapy in a Patient with Chronic Hepatitis B: A Case Report by Brakenhoff, Sylvia M., Chi, Heng, Friederich, Pieter, Doukas, Michail, den Hoed, Caroline, Flink, Hajo J., de Knegt, Robert J., de Man, Robert A.

“…Abstract Introduction: Emerging evidence suggests that long-term nucleos(t)ide analogue (NA) therapy can be ceased in a selective group of chronic hepatitis B…”
Get full text

Close Monitoring of Hepatitis B Surface Antigen Levels Helps Classify Flares During Peginterferon Therapy and Predicts Treatment Response by Sonneveld, Milan J., Zoutendijk, Roeland, Flink, Hajo J., Zwang, Louwerens, Hansen, Bettina E., Janssen, Harry L. A.

“…Background. Alanine aminotransferase (ALT) flares occur frequently during peginterferon (PEG-IFN) therapy. We related occurrence of flares to presence of…”
Get full text

Sustained HBeAg and HBsAg Loss After Long-term Follow-up of HBeAg-Positive Patients Treated With Peginterferon α-2b by Buster, Erik H.C.J, Flink, Hajo J, Cakaloglu, Yilmaz, Simon, Krzysztof, Trojan, Jörg, Tabak, Fehmi, So, Thomas M.K, Feinman, S. Victor, Mach, Tomasz, Akarca, Ulus S, Schutten, Martin, Tielemans, Wanda, van Vuuren, Anneke J, Hansen, Bettina E, Janssen, Harry L.A

“…Background & Aims: The aim of this study was to evaluate the long-term sustainability of response in patients with hepatitis B e antigen (HBeAg)-positive…”
Get full text

Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b by Buster, Erik H C J, Flink, Hajo J, Cakaloglu, Yilmaz, Simon, Krzysztof, Trojan, Jörg, Tabak, Fehmi, So, Thomas M K, Feinman, S Victor, Mach, Tomasz, Akarca, Ulus S, Schutten, Martin, Tielemans, Wanda, van Vuuren, Anneke J, Hansen, Bettina E, Janssen, Harry L A

“…The aim of this study was to evaluate the long-term sustainability of response in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B…”
Get full text

Treatment with Peg-Interferon α-2b for HBeAg-Positive Chronic Hepatitis B: HBsAg Loss Is Associated with HBV Genotype by FLINK, Hajo J, VAN ZONNEVELD, Monika, HANSEN, Bettina E, DE MAN, Robert A, SCHALM, Solko W, JANSSEN, Harry L. A

Get full text

Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype by Flink, Hajo J, van Zonneveld, Monika, Hansen, Bettina E, de Man, Robert A, Schalm, Solko W, Janssen, Harry L A

“…Hepatitis B surface antigen (HBsAg) loss is the hallmark of a complete response to antiviral therapy for chronic hepatitis B. In this study, we investigated…”
Get full text

Antibacterial gauzes are effective in preventing infections after percutaneous endoscopic gastrostomy placement: a retrospective analysis by Strijbos, Denise, Schoon, Erik J, Curvers, Wouter, Friederich, Pieter, Flink, Hajo J, Stronkhorst, Arnold, Gilissen, Lennard P.L

“…OBJECTIVESThe most common complication after percutaneous endoscopic gastrostomy (PEG) placement is peristomal wound infection (up to 40% without antibiotic…”
Get full text

Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients by Buster, Erik H C J, Flink, Hajo J, Simsek, Halis, Heathcote, E Jenny, Sharmila, Sachithanandan, Kitis, George E, Gerken, Guido, Buti, Maria, de Vries, Richard A, Verhey, Elke, Hansen, Bettina E, Janssen, Harry L A

“…Treatment with pegylated interferon (PEG-IFN) alpha-2b results in hepatitis B e antigen (HBeAg) loss in 36% of patients at 6 months post treatment. The aim of…”
Get full text

Early HBeAg Loss During Peginterferon α-2b Therapy Predicts HBsAg Loss: Results of a Long-Term Follow-Up Study in Chronic Hepatitis B Patients by BUSTER, Erik H. C. J, FLINK, Hajo J, HANSEN, Bettina E, JANSSEN, Harry L. A, SIMSEK, Halis, HEATHCOTE, E. Jenny, SHARMILA, Sachithanandan, KITIS, George E, GERKEN, Guido, BUTI, Maria, DE VRIES, Richard A, VERHEY, Elke

Get full text

Successful Treatment with Peginterferon alfa-2b of HBeAg-positive HBV Non-Responders to Standard Interferon or Lamivudine by FLINK, Hajo J, HANSEN, Bettina E, SCHALM, Solko W, JANSSEN, Harry L. A, HEATHCOTE, E. Jenny, FEINMAN, S. Victor, SIMSEK, Halis, KARAYALCIN, Selim, MACH, Tomasz, LEEMANS, Wim F, DE MAN, Robert A, VERHEY, Elke

“…Antiviral therapy leads to HBeAg seroconversion in 10-40% of the patients with HBeAg-positive chronic hepatitis B. Nonresponse may result in progression of…”
Get full text

The effect of pegylated interferon-α on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection by Leemans, Wilhelmus F., Flink, Hajo J., Janssen, Harry L.A., Niesters, Hubert G.M., Schalm, Solko W., de Man, Robert A.

“…To determine the response to pegylated interferon-α treatment of HBeAg-positive hepatitis B patients with proven lamivudine resistance. Sixteen HBeAg-positive…”
Get full text

Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine by Van Zonneveld, Monika, Zondervan, Pieter E, Cakaloglu, Yilmaz, Simon, Christopher, Akarca, Ulus S, So, Thomas MK, Flink, Hajo J, De Man, Robert A, Schalm, Solko W, Janssen, Harry LA

“…: Background: The effect of pegylated interferon or its combination with lamivudine on liver histology of patients with chronic hepatitis B (CHB) is unknown…”
Get full text

THU-138 The male-to-female ratio among patients with primary biliary cholangitis depends on age by Werner, Ellen, de Veer, Rozanne C., van Hooff, Maria C., Beuers, Ulrich, Drenth, Joost P.H., Cuperus, Frans J.C., van Hoek, Bart, Veldt, Bart J., Kempt-Kropp, Michael, van Meer, Suzanne, Verdonk, Robert C., Flink, Hajo J., Vrolijk, Jan Maarten, Gevers, Tom J.G., Ponsioen, Cyriel Y., Borg, Martijn J. ter, Soufidi, Khalida, Boersma, Femke, de Jonge, Hendrik J.M., Wolfhagen, Frank H.J., Baak, L.C., Onderwater, Susanne L., van Bergeijk, Jeroen D., van Putten, Paul G., de Bruin, Gijs J., Adang, Rob P.R., Pages, Nieves Aparicio, de Boer, Wink, Borg, Frank ter, van Soest, Hanneke, Janssen, Harry L.A., Hansen, Bettina E., Erler, Nicole S., van der Meer, Adriaan J.

Get full text

THU-109 Increasing prevalence of primary biliary cholangitis in The Netherlands by de Veer, Rozanne C., van Hooff, Maria C., Werner, Ellen, Beuers, Ulrich, Drenth, Joost P.H., Cuperus, Frans J.C., van Hoek, Bart, Veldt, Bart J., Kempt-Kropp, Michael, van Meer, Suzanne, Verdonk, Robert C., Flink, Hajo J., Vrolijk, Jan Maarten, Gevers, Tom J.G., Ponsioen, Cyriel Y., Borg, Martijn J. ter, Soufidi, Khalida, Boersma, Femke, de Jonge, Hendrik J.M., Wolfhagen, Frank H.J., Baak, L.C., Onderwater, Susanne L., van Bergeijk, Jeroen D., van Putten, Paul G., de Bruin, Gijs J., Adang, Rob P.R., Pages, Nieves Aparicio, de Boer, Wink, Borg, Frank ter, van Soest, Hanneke, Janssen, Harry L.A., Hansen, Bettina E., Erler, Nicole S., van der Meer, Adriaan J.

Get full text

THU-100 Factors associated with the real-world biochemical response to fibrate therapy in primary biliary cholangitis by van Hooff, Maria C., de Veer, Rozanne C., Werner, Ellen, Beuers, Ulrich, Drenth, Joost P.H., Cuperus, Frans J.C., van Hoek, Bart, Veldt, Bart J., Klemt-Kropp, Michael, van Meer, Suzanne, Verdonk, Robert C., Flink, Hajo J., Vrolijk, Jan Maarten, Gevers, Tom J.G., Ponsioen, Cyriel Y., van Rooij, Janne, Kerbert-Dreteler, Marjo J., Nicolaas, Jerome Sint, De Vree, Marleen, de Vries, Elsemieke S., Friederich, Philip W., Tielemans, Merel M., Aktas, Huseyin, Hotho, Daphne M., de Wit, Ulrike, Kuyvenhoven, Johan P.H., Abraham, Sunje, Kuiper, Edith M.M., Schmittgens, Stephan, Alderslieste, Yasser A., Janssen, Harry L.A., Hansen, Bettina E., Erler, Nicole S., van der Meer, Adriaan J.

Get full text

THU-120-YI The impact of ursodeoxycholic acid on biochemistry of patients with primary biliary cholangitis in a nationwide cohort by Werner, Ellen, van Hooff, Maria C., van der Maas, Gerjan J., de Veer, Rozanne C., Beuers, Ulrich, Drenth, Joost P.H., Cuperus, Frans J.C., van Hoek, Bart, Veldt, Bart J., Klemt-Kropp, Michael, van Meer, Suzanne, Verdonk, Robert C., Flink, Hajo J., Vrolijk, Jan Maarten, Gevers, Tom J.G., Ponsioen, Cyriel Y., de Kort, Sander, van Putten, Paul G., Cahen, Djuna L., van der Waaij, Lauren A., Thio, Hans H.K., Schreuder, Tim C.M.A., van Dam, Lisette J.H., Epping, Ludger S.M., Jurgens, Matthias C., Cazemier, Marcel, van Kemenade, J., Kuiper, Edith M.M., Beukema, Menno, Borg, Martijn J. ter, Soufidi, Khalida, Janssen, Harry L.A., Hansen, Bettina E., Erler, Nicole S., van der Meer, Adriaan J.

Get full text

Early HBeAg Loss During Peginterferon [alpha]-2b Therapy Predicts HBsAg Loss: Results of a Long-Term Follow-Up Study in Chronic Hepatitis B Patients by Buster, Erik H C J, Flink, Hajo J, Simsek, Halis, Heathcote, E Jenny, Sharmila, Sachithanandan, Kitis, George E, Gerken, Guido, Buti, Maria, De Vries, Richard A, Verhey, Elke, Hansen, Bettina E, Janssen, Harry L A

“…OBJECTIVES:Treatment with pegylated interferon (PEG-IFN) α-2b results in hepatitis B e antigen (HBeAg) loss in 36% of patients at 6 months post treatment. The…”
Get full text

Treatment with Peg-Interferon [alpha]-2b for HBeAg-Positive Chronic Hepatitis B: HBsAg Loss Is Associated with HBV Genotype by Flink, Hajo J, Van Zonneveld, Monika, Hansen, Bettina E, De Man, Robert A, Schalm, Solko W, Janssen, Harry La

“…BACKGROUND AND AIMS:Hepatitis B surface antigen (HBsAg) loss is the hallmark of a complete response to antiviral therapy for chronic hepatitis B. In this…”
Get full text

Clinical Studies: Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine by van Zonneveld, Monika, Zondervan, Pieter E, Cakaloglu, Yilmaz, Simon, Christopher, Akarca, Ulus S, So, Thomas MK, Flink, Hajo J, de Man, Robert A, Schalm, Solko W, Janssen, Harry LA

“…The effect of pegylated interferon or its combination with lamivudine on liver histology of patients with chronic hepatitis B (CHB) is unknown. In a…”
Get full text

A Fatal Outcome after Cessation of Nucleotide Analogue Therapy in a Patient with Chronic Hepatitis B: A Case Report by Brakenhoff, Sylvia M, Chi, Heng, Friederich, Pieter, Doukas, Michail, den Hoed, Caroline, Flink, Hajo J, de Knegt, Robert J, de Man, Robert A

“…IntroductionEmerging evidence suggests that long-term nucleos(t)ide analogue (NA) therapy can be ceased in a selective group of chronic hepatitis B (CHB). This…”
Get full text